SEARCH

SEARCH BY CITATION

Keywords:

  • Systemic lupus erythematosus;
  • Thrombosis;
  • Risk factors

Abstract

  1. Top of page
  2. Abstract
  3. INTRODUCTION
  4. PATIENTS AND METHODS
  5. RESULTS
  6. DISCUSSION
  7. REFERENCES

Objective

To investigate the thrombotic tendency in patients with systemic lupus erythematosus (SLE) by evaluating congenital or acquired abnormalities associated with an increased risk of venous and/or arterial thrombosis.

Methods

A total of 57 patients with SLE were included in the study. Twenty-one patients (37%) had a history of arterial and/or venous thrombosis and 36 patients (63%) did not have such a history. Sera from 50 healthy controls were examined. Protein C, protein S, antithrombin, D-dimer, fibrinogen, homocysteine, anticardiolipin antibodies (aCL), lupus anticoagulant (LAC), prothrombin G20210A, and methylenetetrahydrofolate reductase (MTHFR) C677T gene mutation were evaluated.

Results

Protein C, antithrombin, fibrinogen, D-dimer, and homocysteine levels were significantly higher in patients with SLE than in controls. A prothrombin mutation was observed in 2 (4%) of 50 controls and in 6 (11%) of 57 patients. A significantly higher prevalence (P = 0.036) of MTHFR homozygous mutation was observed in patients with SLE (14 [25%] of 57) in comparison with controls (4 [8%] of 50). IgG-aCL and IgM-aCL levels were significantly higher in patients with SLE than in controls (P < 0.0001). The presence of medium-high (≥20 IgG phospholipid units/ml) IgG-aCL antibody titers was significantly higher (P = 0.005) in patients with thrombosis (11 [52%] of 21) than in patients without (5 [14%] of 36) thrombosis. LAC was present in 22 (38.5%) of 57 patients and in none of 50 controls.

Conclusion

In this study, we confirm the association between thrombosis and IgG-aCL at medium-high titers and suggest that the coexistence of other risk factors can affect the expression of thrombosis in patients with SLE.


INTRODUCTION

  1. Top of page
  2. Abstract
  3. INTRODUCTION
  4. PATIENTS AND METHODS
  5. RESULTS
  6. DISCUSSION
  7. REFERENCES

Systemic lupus erythematosus (SLE) is an autoimmune disease of unknown etiology that involves multiple organ systems. Arterial and venous thromboembolism is a well-known clinical entity in SLE, with a prevalence >10%. This prevalence may even exceed 50% in high-risk patients (1, 2). Thrombosis in SLE occurs through 3 major conditions: hypercoagulability, premature atherosclerosis, and vasculitis (3). Hypercoagulability is most commonly secondary to the presence of lupus anticoagulant (LAC) and anticardiolipin antibodies (aCL) (3); the interaction between the antibodies to phospholipid–protein complexes and antigen targets on endothelial cells, platelets, or components of coagulation cascade can mediate the vascular injury. Nevertheless, the pathogenesis of the thrombotic tendency and vessel damage in SLE is not yet completely clarified. In recent years, research has focused on the role of other disease-associated risk factors and predisposing conditions such as hypertension, corticosteroid treatment, hyperhomocysteinemia, decreased protein S concentration, and different hemostatic markers (4–6). Endothelial cells may be injured by high levels of plasma homocysteine (7, 8), and several studies have demonstrated an association between mild hyperhomocysteinemia and occlusive vascular disease (9). Thromboembolic disease is now viewed as a multicausal model, and the thrombotic event seems to be the result of gene–gene and gene–environment interactions (10). Inherited thrombophilia is defined as a genetically determined tendency for development of thromboembolism; the overall prevalence of thrombophilic traits in the general population is ∼10% and the risk of a first thrombotic event increases in the presence of combined defects (10, 11).

This study was carried out to investigate the thrombotic tendency in patients with SLE by evaluating congenital or acquired abnormalities associated with an increased risk of venous and/or arterial thrombosis.

PATIENTS AND METHODS

  1. Top of page
  2. Abstract
  3. INTRODUCTION
  4. PATIENTS AND METHODS
  5. RESULTS
  6. DISCUSSION
  7. REFERENCES

Study population.

The study group comprised 57 consecutive Italian outpatients with SLE who were admitted for routine visits to our Immunologic Department. All patients fulfilled 4 or more of the American College of Rheumatology's criteria for the classification of SLE (12), as updated according to the criteria described by Hochberg (13). Antiphospholipid syndrome (APS) was defined as positive antiphospholipid antibodies (at least 2 positive tests 6 weeks apart for IgG-aCL and/or IgM-aCL at medium-high levels and/or LACs) with documented obstetric and/or thrombotic complications, according to the Sapporo criteria (14). The main clinical characteristics are shown in Table 1.

Table 1. Main clinical characteristics of the 57 patients with systemic lupus erythematosus*
  • *

    Except where indicated otherwise, values are the number (percentage).

Sex, no. female/male49/8
Median age, years (range)40 (17–59)
Disease duration, years (range)9.9 (1–40)
Skin manifestations 
 Butterfly rash35 (61.4)
 Discoid lesions23 (40.3)
 Photosensitivity40 (70.1)
 Mouth ulcers2 (3.5)
Arthralgias/arthritis54 (94.7)
Serositis 
 Pleurisy7 (12.3)
 Pericarditis6 (10.5)
Renal disease21 (36.8)
Neuropsychiatric manifestations44 (77.1)
Antiphospholipid syndrome18 (31.6)
 Recurrent pregnancy loss (n = 49)7 (14.3)
 Arterial and venous thrombosis (n = 49)13 (26.5)
Hematologic abnormalities 
 Hemolytic anemia3 (5.2)
 Leukopenia13 (22.8)
 Lymphopenia8 (14)
 Thrombocytopenia12 (21)
Immunologic abnormalities 
 Antinuclear antibodies57 (100)
 Anti–double-stranded DNA36 (63.1)
 Anti-Sm10 (17.5)

At study entry, all patients were receiving oral prednisolone. Eight patients were additionally being treated with hydroxychloroquine; 9 patients were being treated with cyclosporine; 6 patients were being treated with cyclophosphamide; and 5 patients were being treated with cyclophosphamide and cyclosporine. None of the patients were receiving oral anticoagulants at the time of the study. The control group consisted of 50 age- and sex-matched healthy Italian blood donors.

Evaluation for thromboembolic events.

Twenty-one of the 57 patients (37%) had a history of thrombosis. Clinical histories revealed that venous thromboembolism had occurred in 12 patients, (deep vein thrombosis in 6 and pulmonary embolism in 6). Arterial thrombosis had occurred in 11 patients. In the entire group, 2 patients had both arterial and venous thrombosis. Thrombosis was diagnosed based on clinical manifestations and findings on duplex scanning, radioisotope venography, and radioisotope lung scanning.

At the time of the first evaluation, differences between the entire SLE group (n = 57) and controls were analyzed. Then, multiple comparisons between SLE patients with thrombosis (group 1) and SLE patients without thrombosis (group 2) and controls were performed. All subjects gave informed consent before entering the study.

Laboratory testing.

All samples were coded, and investigators performing the assays were blinded to the presence or the absence of thrombosis. Each specific test was performed in the same laboratory throughout the study. Each session of laboratory tests included either study controls or a laboratory control represented by pooled plasma. With respect to free protein S, protein C, antithrombin, prothrombin time (PT), partial thromboplastin time (PTT), fibrinogen, homocysteine, and D-dimer, the interassay coefficient of variation was always <5%. IgG-aCL and IgM-aCL were detected on the same day, using the same batches of reagents.

Plasma samples.

In all patients, blood samples were obtained at the time of entry into the study. Venous blood was obtained using vacuum tubes containing 0.015M buffered sodium citrate solution. Plasma samples were obtained by centrifugation and aliquots were stored at –70°C.

Free protein S.

The evaluation of free protein S was performed with the Asserachrom Free Protein S kit (Diagnostica Stago, Asnières-sur-Seine, France), which permits a quantitative evaluation of free protein S by a 1-step sandwich enzyme-linked immunosorbent assay (ELISA).

Antithrombin.

Automated determination of antithrombin activity in the plasma was performed using the STA antithrombin kit (Diagnostica Stago).

Protein C.

Automated determination of protein C activity in plasma was performed using the STA Coagulative Protein C kit (Diagnostica Stago).

Homocysteine.

The plasma concentration of homocysteine was evaluated by the IMx homocysteine assay (Abbott, Abbott Park, IL), which is a fluorescence polarization immunoassay. The tests were performed on the IMx Analyser (Abbott). An elevated homocysteine concentration in plasma was defined as a fasting plasma concentration >15 μmoles/liter (15).

Factor V Leiden, activated protein C resistance (APCr), prothrombin G20210A mutation, and MTHFR C677T gene mutation assay.

Factor V Leiden, prothrombin G20210A, and methylenetetrahydrofolate reductase (MTHFR) gene mutations were analyzed by polymerase chain reaction (PCR) technique, using specific Nuclear Laser Medicine kits (Nuclear Laser Medicine, Settala, Milan, Italy). DNA was extracted from white blood cells, amplified by adding Taq, and subjected to the amplification program by PCR. We obtained 3 lines, 1 for Factor V Leiden (222 bases), 1 for MTHFR (200 bases), and 1 for prothrombin (174 bases). The amplified products were subjected to hybridization, and after washing, to color development by adding conjugate. In relation to the optical density (OD) reading, it is possible to establish whether the sample contains the specific mutation in a heterozygous or homozygous state.

An activated protein C resistance (APC-r) assay was performed using an activated partial thromboplastin time (APTT)–based assay. The APTT was measured in the presence and absence of activated protein C and in a calcified medium using an STA-Staclot APCr kit (Diagnostica Stago). The test was performed with undiluted patient plasma. Plasma with a clotting time <120 seconds was considered APCr positive.

Detection of LAC.

The determination of LAC followed the criteria of the Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society of Thrombosis and Haemostasis (16). Screening assays included the kaolin clotting time, dilute APTT, dilute PT, and 2 dilute Russell viper venom times; all tests were repeated in a 1:1 mix with normal plasma, and positive test results were confirmed with the same reagent in the presence of excess phospholipids. At least one test system result had to be positive in all steps for a patient to be considered LAC positive.

Anticardiolipin antibodies.

Sera were stored at −80°C until used. Detection, characterization of specificity, and determination of the IgG or IgM isotype of aPL were performed by ELISA, using commercially available kits (Orgentec-Diagnostika, Mainz, Germany). For aCL determination, the microplates were coated with highly purified cardiolipin and saturated with highly purified human β2-glycoprotein I.

Combined calibrators with IgG and IgM class aCL, ranging from 7.5 to 120 IgG phospholipid (GPL) units/ml and from 5 to 80 IgM phospholipid (MPL) units/ml, respectively, were supplied by the manufacturer (Orgentec-Diagnostika). All samples were analyzed in duplicate. After a 30-minute incubation at room temperature, the microplates were washed 3 times with 300 μl of wash buffer; then 100 μl of horseradish peroxidase–conjugated rabbit anti-human IgG or IgM was added to each well. After a 15-minute incubation, plates were washed, and a chromogenic substrate solution containing 3,3′,5,5′-tetramethylbenzidine was dispensed into the wells. Color development was stopped by adding 100 μl of 1M hydrochloric acid and letting it stand for 5 minutes. The OD was read at 450 nm with a Titertek Multiskan plate reader (Flow Laboratories, Irvine, UK). A standard curve was established using the above-mentioned combined calibrators with IgG and IgM class. Values ≥10 GPL/MPL units/ml were considered positive. This cutoff was higher than the 99th percentile of sera from 50 controls for both IgG and IgM antibodies. According to Harris (17), IgG-aCL or IgM-aCL values <20 units/ml were considered low positive, whereas values ≥20 units/ml were considered medium-high positive.

Statistical analysis.

Statistical analysis was performed using the StatSoft program (StatSoft, Tulsa, OK) or version 3.0 of GraphPad Prism software (GraphPad Software, San Diego, CA). According to the Gaussian or non-Gaussian distribution, 2-group comparisons for continuous variables were analyzed by Student's t-test or the Mann-Whitney U test, respectively, whereas for multiple comparisons, analysis of variance with Bonferroni post hoc test or the Kruskal-Wallis test with Dunn's post hoc test were used. Comparisons for categorical variables were analyzed by Fisher's exact test. P values less than 0.05 were considered statistically significant.

RESULTS

  1. Top of page
  2. Abstract
  3. INTRODUCTION
  4. PATIENTS AND METHODS
  5. RESULTS
  6. DISCUSSION
  7. REFERENCES

Coagulation parameters and homocysteine levels.

Protein S showed no significant differences between patients with SLE (mean ± SD 92.8 ± 30%) and controls (91.7 ± 15.2%), whereas protein C and antithrombin levels were significantly higher in patients with SLE than in controls (for protein C, patients 107.7 ± 19.5%, controls 95.6 ± 12.8% [P = 0.0003]; for antithrombin, patients 109 ± 11.7%, controls 96.4 ± 6% [P < 0.0001]) (Figure 1, panel A and B). The PT in patients with SLE (95.2 ± 14.1%) was not significantly different in comparison with controls (96.3 ± 8.7%), whereas PTT was significantly higher in patients than in controls (42.6 ± 15.6 seconds and 33.8 ± 3.4 seconds, respectively; P = 0.0003) (Figure 1, panel C). Levels of fibrinogen (Figure 2, panel A), D-dimer (Figure 2, panel B), and homocysteine (Figure 2, panel C) were significantly higher in SLE than in controls (for fibrinogen, patients 359.7 ± 83.5 mg/dl, controls 275 ± 53.8 mg/dl [P < 0.0001]; for D-dimer, patients 0.58 ± 0.66 μg/mL, controls 0.32 ± 0.14 μg/mL [P = 0.01]; for homocysteine, patients 10.7 ± 4.1 μm/liter, controls 6.7 ± 2.1 μm/liter [P < 0.0001]).

thumbnail image

Figure 1. A, Protein C; B, antithrombin, and C, partial thromboplastin time in 50 control subjects (open circles) and 57 patients with systemic lupus erythematosus (SLE) (solid circles). Horizontal lines represent the mean values. According to the distribution of values, significance of the differences was evaluated by Student's t-test (Figures A, B) or by Mann-Whitney U test (Figure C). CTR = controls.

Download figure to PowerPoint

thumbnail image

Figure 2. A, Fibrinogen; B, D-dimer; and C, homocysteine in 50 control subjects (open circles) and 57 patients with systemic lupus erythematosus (SLE) (solid circles). Horizontal lines represent the mean values. According to the distribution of values, significance of the differences was evaluated by Student's t-test (Figure B) or by Mann-Whitney U test (Figures A, C). CTR = controls.

Download figure to PowerPoint

With respect to homocysteine levels, patients with renal dysfunction showed higher levels (11.8 ± 5.2 μm/liter) in comparison with patients without renal dysfunction (10.1 ± 3.3 μm/liter), even though the difference was not significant (P = 0.15). When multiple comparisons among controls and patients with and those without thrombosis were performed, no significant differences between group 1 and group 2 were found, even though higher median values of homocysteine and D-dimer were observed in SLE patients with thrombosis (Table 2).

Table 2. Comparison among coagulation factors in patients with and without thrombosis, patients who are aCL positive and aCL negative, and controls*
 ThrombosisaCLControls n = 50
Yes (n = 21)No (n = 36)Yes (n = 29)No (n = 28)
  • *

    Values are the mean ± SD (range). aCL = anticardiolipin antibodies; PT = prothrombin time; PTT = partial thromboplastine time

  • Significantly higher in comparison with aCL negative patients (P < 0.001).

Protein S, %101.7 ± 37.8 (55–169)87.6 ± 23.5 (51–160)94.2 ± 31 (55–169)91.3 ± 29.3 (51–165)91.7 ± 15.2 (70–120)
Protein C, %110 ± 19 (70–150)101.7 ± 37.8 (55–169)109.6 ± 21.2 (70–150)105.8 ± 17.8 (63–140)95.6 ± 12.8 (71–120)
PT, %95.4 ± 17 (35–118)95.1 ± 12.5 (44–117)90.3 ± 17.3 (35–118)100.3 ± 7 (88–117)96.3 ± 8.7 (79–114)
PTT, seconds43.3 ± 12.3 (27.4–66)42.3 ± 17.8 (27.2–120)49.8 ± 18.6 (29.6–120)35.1 ± 5.6 (27.2–49)33.8 ± 3.44 (28–40)
Fibrinogen, mg/dl375.8 ± 105.1 (264–722)350 ± 67.9 (239–501)342 ± 68.7 (239–543)378 ± 94.4 (265–722)275.6 ± 53.9 (159–400)
Antithrombin, %109.2 ± 11.5 (91–135)108.9 ± 11.9 (92–139)108.9 ± 12.1 (91–135)109.1 ± 11.4 (92–139)96.4 ± 6 (82–106)
D-dimer, μg/ml0.73 ± 0.86 (0.22–3.83)0.49 ± 0.5 (0.22–3.22)0.48 ± 0.32 (0.22–1.32)0.69 ± 0.88 (0.83–3.83)0.32 ± 0.14 (0.1–0.55)
Homocysteine, μm/liter12.1 ± 4.1 (6.1–19.7)9.9 ± 4 (4.4–23.2)10.9 ± 4.1 (4.4–23.2)10.5 ± 4.3 (5.6–21.6)6.8 ± 2.1 (2.9–10.8)

Factor V Leiden, APCr, prothrombin G20210A mutation, and MTHFR polymorphism.

APCr was detected in 1 (2%) of 50 controls and 2 (3%) of 57 patients; all these patients were positive for Factor V Leiden. Therefore, no patients were considered to have acquired APC resistance. The prevalence of prothrombin mutation was not significantly different between patients with SLE and controls (2 [4%] of 50 controls and 6 [11%] of 57 patients).

With respect to MTHFR, a significantly higher prevalence (P = 0.036) of homozygous mutation was observed in patients with SLE (14 [25%] of 57) compared with controls (4 [8%] of 50), whereas no significant difference was found regarding the prevalence of heterozygous mutation (24 [42%] of 57 patients and 20 [40%] of 50 controls). The differences between patients with and without thrombosis were not significant.

Anticardiolipin antibodies.

Raised levels of IgG-aCL and IgM-aCL were found in 27 (47%) of 57 and in 12 (21%) of 57 patients with SLE, respectively, and in 0 of 50 controls. The differences were statistically significant (P < 0.0001 and P = 0.0003, respectively). The prevalence of both IgG-aCL and IgM-aCL was higher in group 1 (13 [62%] of 21 and 6 [29%] of 21, respectively) compared with group 2 (14 [39%] of 36 and 6 [17%] of 36, respectively), even though the difference was not significant.

Regarding aCL antibody titers, the presence of medium-high (≥20 GPL units/ml) IgG-aCL antibody titer was significantly higher in group 1 than in group 2 (11 [52%] of 21 and 5 [14%] of 36, respectively; P = 0.005).

LAC was present in 22 (38.5%) of 57 patients and 0 of 50 controls, whereas there was no significant difference in the prevalence of LAC between group 1 (10 [47.6%] of 21 patients) and group 2 (12 [33.3%] of 36 patients).

DISCUSSION

  1. Top of page
  2. Abstract
  3. INTRODUCTION
  4. PATIENTS AND METHODS
  5. RESULTS
  6. DISCUSSION
  7. REFERENCES

Thrombosis is a common manifestation in patients with SLE. The identification of thrombophilic risk factors in these patients is clinically useful in determining those in whom thrombosis would be more likely to occur (18). Several blood parameters have been proposed to predict the occurrence of thrombosis, including the presence of LAC, aCL, and anti–β2-glycoprotein I antibodies. In contrast, it is noteworthy that approximately 40% of adults with SLE who are negative for aPL antibodies are diagnosed with thrombosis (19, 20). Thus, the precise mechanism(s) responsible for thrombosis in these patients remains unclear.

In our study, we examined the presence of thromboembolic risk factors in patients with SLE with or without a history of thrombosis, and we found modifications regarding several parameters analyzed. We documented alterations responsible for or markers of hypercoagulability, including raised levels of fibrinogen, homocysteine, and D-dimer, as well as increased levels of natural anticoagulant protein, such as protein C and antithrombin.

Of interest, it has been recently demonstrated that increased thrombin generation accompanied by heightened activity of antithrombin occurs in venous blood of patients with SLE and APS (21). The authors suggest that in these patients, the increased activities of antithrombin III are secondary to augmented thrombin generation and serve to protect these patients from frequent thromboembolic episodes (21).

In the current study, no significant decrease in the plasma concentration of the total protein S was observed. Tomas et al (22) reported that in patients with SLE, protein C, antithrombin, and total protein S antigenic levels were in the normal range, but other authors have observed alterations in these protein systems (23, 24). Therefore, our results do not exclude a possible role of these proteins in the pathogenesis of thrombosis; further studies could elucidate the coagulation picture in patients with SLE.

D-dimer levels significantly increased in our patients compared with controls. In particular, assuming 0.55 μg/ml (the highest value found in our controls) as cutoff, we documented high concentrations of D-dimer in 15 (26%) of 57 patients, with a higher percentage in patients with (43%) than in those without (17%) a history of thrombosis. Elevated levels of D-dimer are usually detectable during the thrombotic events; thus, raised concentrations of D-dimer in our patients could indicate a subclinical activation of a blood coagulation system without overt thrombotic manifestations. This result suggests that both a prethrombotic state and a compensatory fibrinolytic process secondary to subclinical intravascular coagulation might coexist in SLE, as hypothesized by other authors (4). The careful followup of patients with elevated D-dimer will make clear the correctness of this hypothesis.

Homocysteine is a nonessential amino acid produced during normal metabolism, and hyperhomocysteinemia is frequently associated with arterial and venous thrombosis. Prothrombotic activities may be attributable to either direct toxic effect on endothelium or indirect effects (9).

In the present study, we found increased homocysteine levels in patients with SLE, which is consistent with results previously reported by other investigators (9, 25). When considering a cutoff level of 14.1 μmoles/liter as suggested by Petri et al (9) and Selhub et al (26), we found hyperhomocysteinemia in 8 (16%) of 57 of patients, which is almost the same percentage reported by these authors, who detected raised homocysteine concentrations in 15% of patients.

The total homocysteine concentration in the plasma of healthy individuals varies with age, sex, geographic area, and genetic factors. Some authors have recently proposed a lower cutoff for homocysteine, adjusted according to the top 95th percentile of the distribution of the control group (27). Based on this criterion, the prevalence of hyperhomocysteinemia was significantly higher in SLE patients with thrombosis. The 95th percentile of homocysteine levels in our control group was 10.7 μmoles/liter. According to this cutoff, 11 (52%) of 21 patients with and 10 (27.7%) of 36 patients without thrombosis showed raised levels of homocysteine.

With respect to the frequency of MTHFR genotypes, we found an homozygous mutant (+/+) in 25% of patients, a percentage higher than that reported by Fijnheer et al who demonstrated the homozygous mutant in 8% of their cohort of patients (25). However, in agreement with the results of these authors, we found no significant differences between patients with and without thrombosis. Therefore, the actual role of MTHFR gene mutation in SLE remains to be better elucidated.

The prothrombin mutation variant was present in 6 patients, which is higher than the prevalence in the control group (11% versus 4%). Recently, one study found that the presence of mutated allele of the prothrombin gene was higher in patients with APS when compared with controls, suggesting that prothrombin variant could increase the risk of thrombosis in these patients (18).

We investigated the presence of resistance to activated protein C in our SLE population. Resistance to activated protein C is defined as a decreased anticoagulant response to the activated protein C pathway (28). Hereditary APCr is caused by the Factor V Leiden mutation and it is currently regarded as the most frequent cause of familial thrombosis (11, 29–31); acquired APCr, a phenotypic APCr that occurs in the absence of the Factor V Leiden mutation, has been reported in patients with defined APS (27, 32–35). In our study, APCr was detected in 1 (2%) of 50 controls and 2 (3%) of 57 patients. Because all these subjects were positive for Factor V Leiden, they were not considered to have acquired APCr.

Male et al (35) determined the congenital or acquired APCr frequency in pediatric patients with SLE and its association with aPL. In their study, the authors reported that acquired APCr was present in 31% of pediatric patients with SLE, none of whom had Factor V Leiden. APCr was significantly associated with LAC and thrombotic events (35–37). Some authors have hypothesized that APCr may have been the result of thromboembolic events in some patients, reflecting an acute phase response (35, 38). A limitation of our study is the retrospective design; however, even in other studies, some patients had thrombotic events identified retrospectively. Also, in retrospective studies, APCr testing was not available for patients who were receiving warfarin therapy. Therefore, prospective studies would be required to test the effectiveness of using APCr to predict thrombosis in patients with SLE and to accurately define the mechanism of acquired APCr.

Our study confirms observations concerning the role of aCL at high titer in the development of thrombosis in patients with SLE, even though a positive correlation of aCL with thrombosis is well known (39, 40). In a previous study of 87 patients with SLE, we have demonstrated that IgG-aCL, when taken at any rate of positivity (low, medium, high titer), were not significantly associated with thrombosis. However, when only aCL at medium-high titer were taken into account, a significant association was demonstrated (20). In the present study, we confirm the association between thrombosis and IgG-aCL at medium-high titer.

Although hypercoagulability associated with the presence of aPL is one of the major factors responsible for thrombosis in patients with SLE, the risk of developing a thrombotic event in aPL-positive patients is likely to be enhanced by the presence of certain procoagulant alterations (3). Some risk factors can be directly related to SLE and/or its treatment, or can be attributable to other common hypercoagulable conditions (41). Indeed, patients with SLE have a thrombotic tendency that is not exclusively associated with aPL. Although in the present study we observed no significant association between a specific thrombophilic risk factor other than aPL and thrombosis, our results still demonstrate that patients with SLE had more than one potentially causative factor involved in thrombogenesis. We suggest that the coexistence of aPL and other risk factors can affect the expression of thrombosis in patients with SLE, and that the development of thrombosis is multifactorial. In fact, the risk of thrombotic events further increases in the presence of combined defects (10). Therefore, patients with SLE require closer followup for potential thrombotic complications to identify patients with more than one risk factor for thrombosis. This could be important because some risk factors, such as hyperhomocysteinemia, are potentially modifiable (27, 42).

REFERENCES

  1. Top of page
  2. Abstract
  3. INTRODUCTION
  4. PATIENTS AND METHODS
  5. RESULTS
  6. DISCUSSION
  7. REFERENCES
  • 1
    Wahl DG, Bounameaux H, de Moerloose P, Sarasin FP. Prophylactic antithrombotic therapy for patients with systemic lupus erythematosus with or without antiphospholipid antibodies: do the benefits outweigh the risks? A decision analysis. Arch Intern Med 2000; 160: 20428.
  • 2
    Love PE, Santoro SA. Antiphospholipid antibodies: anticardiolipin and the lupus anticoagulant in systemic lupus erythematosus (SLE) and in non-SLE disorders: prevalence and clinical significance. Ann Intern Med 1990; 112: 68298.
  • 3
    Qushmaq K, Esdaile J, Devine DV. Thrombosis in systemic lupus erythematosus: the role of antiphospholipid antibody. Arthritis Care Res 1999; 12: 2129.
  • 4
    Kiraz S, Ertenli I, Benekli M, Haznedaroglu IC, Calguneri M, Celik I et al. Clinical significance of haemostatic markers and thrombomodulin in systemic lupus erythematosus: evidence for a prothrombotic state. Lupus 1999; 8: 73741.
  • 5
    Petri M. Thrombosis and systemic lupus erythematosus: the Hopkins Lupus Cohort perspective. Scand J Rheumatol 1996; 25: 1913.
  • 6
    Belmont HM, Abramson SB, Lie JT. Pathology and pathogenesis of vascular injury in systemic lupus erythematosus: interactions of inflammatory cells and activated endothelium. Arthritis Rheum 1996; 39: 922.
  • 7
    Coppola A, Davi G, de Stefano V, Mancini FP, Cerbone AM, Di Minno G. Homocysteine, coagulation, platelet function, and thrombosis. Semin Thromb Hemost 2000; 26: 24354.
  • 8
    Blom HJ. Consequences of homocysteine export and oxidation in the vascular system. Semin Thromb Hemost 2000; 26: 22732.
  • 9
    Petri M, Roubenoff R, Dallal GE, Nadeau MR, Selhub J, Rosenberg IH. Plasma homocysteine as a risk factor for atherothrombotic events in systemic lupus erythematosus. Lancet 1996; 348: 11204.
  • 10
    De Stefano V, Rossi E, Paciaroni K, Leone G. Screening for inherited thrombophilia: indications and therapeutic implications. Haematologica 2002; 87: 1095108.
  • 11
    Lane DA, Mannucci PM, Bauer KA, Bertina RM, Bochkov NP, Boulyjenkov V, et al. Inherited thrombophilia: part 1. Thromb Haemost 1996; 76: 65162.
  • 12
    Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 12717.
  • 13
    Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus [letter]. Arthritis Rheum 1997; 40: 1725.
  • 14
    Wilson WA, Gharavi AE, Koike T, Lockshin MD, Branch DW, Piette JC, et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum 1999; 42: 130911.
  • 15
    Welch GN, Loscalzo J. Homocysteine and atherothrombosis. N Eng J Med 1998; 338: 104250.
  • 16
    Brandt JT, Triplett DA, Alving B, Scharrer I, and the Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the ISTH. Criteria for the diagnosis of lupus anticoagulants: an update. Thromb Haemost 1995; 74: 118590.
  • 17
    Harris EN. Special report: the Second International Anti-Cardiolipin Standardization Workshop/the Kingston Anti-Phospholipid Antibody Study (KAPS) group. Am J Clin Pathol 1990; 94: 47684.
  • 18
    Torresan M, Machado TF, Siquiera LH, Ozelo MC, Arruda VR, Annichino-Bizzacchi JM. The impact of the search for thrombophilia risk factors among antiphospholipid syndrome patients with thrombosis. Blood Coagul Fibrinolysis 2000; 11: 67982.
  • 19
    Long AA, Ginsberg JS, Brill-Edwards P, Johnston M, Turner C, Denburg JA, et al. The relationship of antiphospholipid antibodies to thromboembolic disease in systemic lupus erythematosus: a cross-sectional study. Thromb Haemost 1991; 66: 5204.
  • 20
    Amoroso A, Mitterhofer AP, Del Porto F, Garzia P, Ferri GM, Galluzzo S, et al. Antibodies to anionic phospholipids and anti-beta2-GPI: association with thrombosis and thrombocytopenia in systemic lupus erythematosus. Hum Immunol 2003; 64: 26573.
  • 21
    Musial J, Swadzba J, Szczeklik A. Adaptative mechanisms counterbalancing enhanced thrombinogenesis in antiphospholipid syndrome. Thromb Res 1998; 90: 934.
  • 22
    Tomas JF, Alberca I, Tabernero MD, Cordero M, Del Pino-Montes J, Vicente V. Natural anticoagulant proteins and antiphospholipid antibodies in systemic lupus erythematosus. J Rheumatol 1998; 25: 5762.
  • 23
    Roubey RA. Autoantibodies to phospholipid-binding plasma proteins: a new view of lupus anticoagulants and other “antiphospholipid” autoantibodies. Blood 1994; 84: 285467.
  • 24
    Oosting JD, Derkesen RH, Bobbink IW, Hackeng TM, Bouma BN, De Groot PG. Antiphospholipid antibodies directed against a combination of phospholipids with prothrombin, protein C, or protein S: an explanation for their pathogenic mechanism? Blood 1993; 81: 261825.
  • 25
    Fijnheer R, Roest M, Haas FJ, De Groot PG, Derksen RH. Homocysteine, methylenetetrahydrofolate reductase polymorphism, antiphospholipid antibodies, and thromboembolic events in systemic lupus erythematosus: a retrospective cohort study. J Rheumatol 1998; 25: 173742.
  • 26
    Selhub J, Jacques PF, Wilson PW, Rush D, Rosenberg IH. Vitamin status and intake as primary determinants of homocysteinemia in an elderly population. JAMA 1993; 270: 26938.
  • 27
    Refai TM, Al-Salem IH, Nkansa-Dwamena D, Al-Salem MH. Hyperhomocysteinaemia and risk of thrombosis in systemic lupus erythematosus patients. Clin Rheumatol 2002; 21: 45761.
  • 28
    Hampton KK, Preston FE, Greaves M. Resistance to activated protein C [letter]. N Engl J Med 1994; 331: 130.
  • 29
    Nojima J, Kuratsune H, Suehisa E, Kawasaki T, Machii T, Kitani T, et al. Acquired activated protein C resistance is associated with the co-existence of anti-prothrombin antibodies and lupus anticoagulant activity in patients with systemic lupus erythematosus. Br J Haematol 2002; 118: 57783.
  • 30
    De Stefano V, Martinelli I, Mannucci PM, Paciaroni K, Chiusolo P, Casorelli I, et al. The risk of recurrent deep venous thrombosis among heterozygous carriers of both factor V Leiden and the G20210A prothrombin mutation. N Engl J Med 1999; 341: 8016.
  • 31
    Martinelli I, Bucciarelli P, Margaglione M, De Stefano V, Castaman G, Mannucci PM. The risk of venous thromboembolism in family members with mutations in the genes of factor V or prothrombin or both. Br J Haematol 2000; 111: 12239.
  • 32
    Ruiz-Arguelles GJ, Garces-Eisele J, Alarcon-Segovia D, Ruiz-Arguelles A. Activated protein C resistance phenotype and genotype in patients with primary antiphospholipid syndrome. Blood Coagul Fibrinolysis 1996; 7: 3448.
  • 33
    Aznar J, Villa P, Espana F, Estelles A, Grancha S, Falco C. Activated protein C resistance phenotype in patients with antiphospholipid antibodies. J Lab Clin Med 1997; 130: 2028.
  • 34
    Picillo U, De Lucia D, Palatiello E, Scuotto A, Marcialis MR, Pezzella S, et al. Association of primary antiphospholipid syndrome with inherited activated protein C resistance. J Rheumatol 1998; 25: 12324.
  • 35
    Male C, Mitchell L, Julian J, Vegh P, Joshua P, Adams M, et al. Acquired activated protein C resistance is associated with lupus anticoagulants and thrombotic events in pediatric patients with systemic lupus erythematosus. Blood 2001; 97: 8449.
  • 36
    Ehrenforth S, Radtke KP, Scharrer I. Acquired activated protein C-resistance in patients with lupus anticoagulants. Thromb Haemost 1995; 74: 7978.
  • 37
    Potzsch B, Kawamura H, Preissner KT, Schmidt M, Seelig C, Muller-Berghaus G. Acquired protein C dysfunction but not decreased activity of thrombomodulin is a possible marker of thrombophilia in patients with lupus anticoagulant. J Lab Clin Med 1995; 125: 5665.
  • 38
    Svensson PJ, Zoller B, Dahlback B. Evaluation of original and modified APC-resistance tests in unselected outpatients with clinically suspected thrombosis and in healthy controls. Thromb Haemost 1997; 77: 3325.
  • 39
    Petri M. Management of thrombosis in antiphospholipid antibody syndrome. Rheum Dis Clin North Am 2001; 27: 63342.
  • 40
    Alarcon-Segovia D. Antiphospholipid syndrome within systemic lupus erythematosus. Lupus 1994; 3: 28991.
  • 41
    Roubey RA. Systemic lupus erythematosus, hypercoagulable states, and antiphospholipid antibodies. Arthritis Care Res 1999; 12: 1556.
  • 42
    Welch GN, Loscalzo J. Homocysteine and atherothrombosis. N Engl J Med 1998; 338: 104250.